Medigene

Medigene AG
legal form	Corporation
ISIN	DE000A1X3W00
founding	1994
Seat	Planegg , Germany
management	Dolores J. Schendel ( CEO ); Horst Domdey ( Chairman of the Supervisory Board );
Number of employees	118 (2018)
sales	7.75 million euros (2018)
Branch	biotechnology
Website	www.medigene.de
	As of December 31, 2018

The MediGene AG is a on the Frankfurt Stock Exchange held biotechnology company headquartered in Martinsried near Munich. The company develops complementary therapy platforms for the treatment of various types and stages of cancer with projects in clinical and preclinical testing. MediGene focuses on the development of personalized, T-cell -gerichteter immunotherapies .

Medigene shares are listed in the Prime Standard of Deutsche Börse and were part of the SDAX index until March 18, 2019 . From February 9, 2009 to September 20, 2010 and from December 19, 2016 to September 24, 2018, the share was also listed in the TecDAX .

history

The company emerged in 1994 from the spin-off of the Munich gene center . One of the founders of the company was the biochemistry professor Horst Domdey . In 2000 the company went public on the Frankfurt Stock Exchange.

Since going public, Medigene AG has taken over:

2001: the US biotech company NeuroVir ( San Diego / USA )
2004: the products and technologies of Munich Biotech AG (Germany)
2006: Avidex Limited ( Oxford / Great Britain )
2014: Takeover of Trianta Immunotherapies GmbH (today Medigene Immunotherapies GmbH)

Individual evidence

↑ ^a ^b Annual Report 2018. (pdf) In: medigene.de. Retrieved September 28, 2019 .
↑ Detect and destroy cancer cells in a targeted manner . In: hu-berlin.de . March 17, 2015. Retrieved February 4, 2016.
↑ Hans Sedlmaier: Medigene goal: immune to cancer . In: focus.de . June 3, 2015. Accessed February 4, 2016.
↑ Medigene researches with the University of Lausanne . In: transkript.de . January 25, 2016. Archived from the original on February 4, 2016. Retrieved on February 4, 2016.
↑ medigene.de

Web links

Medigene AG website

[gb2018-1] Annual Report 2018. (pdf) In: medigene.de. Retrieved September 28, 2019 .

[2] Detect and destroy cancer cells in a targeted manner . In: hu-berlin.de . March 17, 2015. Retrieved February 4, 2016.

[3] Hans Sedlmaier: Medigene goal: immune to cancer . In: focus.de . June 3, 2015. Accessed February 4, 2016.

[4] Medigene researches with the University of Lausanne . In: transkript.de . January 25, 2016. Archived from the original on February 4, 2016. Retrieved on February 4, 2016.

[5] .de